Regeneron Pharmaceuticals, Inc. (REGN)
Automate Your Wheel Strategy on REGN
With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REGN
- Rev/Share 132.0122
- Book/Share 275.4227
- PB 2.198
- Debt/Equity 0.092
- CurrentRatio 4.9267
- ROIC 0.1024
- MktCap 64260937720.0
- FreeCF/Share 28.3046
- PFCF 21.2778
- PE 14.3567
- Debt/Assets 0.072
- DivYield 0.0029
- ROE 0.1477
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | REGN | RBC Capital Mkts | Outperform | Sector Perform | -- | $662 | May 30, 2025 |
| Downgrade | REGN | Wells Fargo | Overweight | Equal Weight | -- | $580 | May 30, 2025 |
| Upgrade | REGN | Citigroup | Neutral | Buy | -- | $700 | May 14, 2025 |
| Resumed | REGN | Cantor Fitzgerald | -- | Overweight | -- | $695 | April 22, 2025 |
| Upgrade | REGN | Leerink Partners | Market Perform | Outperform | $762 | $834 | Feb. 5, 2025 |
| Downgrade | REGN | UBS | Buy | Neutral | $1130 | $738 | Jan. 16, 2025 |
| Resumed | REGN | BofA Securities | -- | Underperform | -- | $565 | Dec. 10, 2024 |
| Downgrade | REGN | Leerink Partners | Outperform | Market Perform | $1175 | $1077 | Sept. 24, 2024 |
News
S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
Published: May 30, 2025 by: Investopedia
Sentiment: Neutral
Major U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Personal Consumption Expenditures data showed that inflation fell more than expected in April.
Read More
Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure
Published: May 30, 2025 by: Market Watch
Sentiment: Negative
Regeneron's stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.
Read More
Itepekimab Failure A Setback For Sanofi And Regeneron
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Negative
Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak sales potential looks like a best-case scenario for itepekimab. Regeneron faces a greater impact, as it is losing an important growth driver in the second half of the decade.
Read More
Regeneron shares plunge after mixed COPD drug trial results
Published: May 30, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) sank nearly 19% on Friday after the company's experimental COPD drug, developed with partner Sanofi SA (ADR) (NYSE:SNY), posted mixed results in two Phase 3 trials—casting doubt on its regulatory path and delaying hopes for a major new revenue stream. The drug, itepekimab, reduced moderate or severe flare-ups by 27% compared to placebo over 52 weeks in the AERIFY-1 study, which enrolled 1,127 former smokers with chronic obstructive pulmonary disease (COPD).
Read More
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
Read More
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM).
Read More
Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D, but the benefits are years away and the risks are immediate. Eylea franchise revenues dropped 26% year-over-year as biosimilars entered the market, stalling overall company growth. Dupixent continues strong growth with new approvals in COPD and CSU, keeping Regeneron profitable despite challenges.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) RBC Capital Markets Global Healthcare Conference May 20, 2025 11:00 AM ET Company Participants Mark Hudson - Senior Director of Investor Relations George D. Yancopoulos - Board Co-Chair, President and Chief Scientific Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Our next featured company, Regeneron, has always been known for its R&D engine.
Read More
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
Read More
Regeneron Buys 23andMe in Bankruptcy Auction
Published: May 19, 2025 by: Investopedia
Sentiment: Negative
Regeneron Pharmaceuticals (REGN) agreed to buy DNA testing company 23andMe for $256 million in a bankruptcy court auction, the company said Monday.
Read More
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions
Published: May 19, 2025 by: New York Post
Sentiment: Negative
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.
Read More
Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal
Published: May 19, 2025 by: Fox Business
Sentiment: Neutral
Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.
Read More
Pharma giant Regeneron to buy 23andMe and its customers' data for $256M
Published: May 19, 2025 by: TechCrunch
Sentiment: Neutral
Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction.
Read More
Cramer's Stop Trading: Regeneron
Published: May 19, 2025 by: CNBC Television
Sentiment: Neutral
Jim Camer breaks down why he's keeping an eye on shares of Regeneron.
Read More
Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
Published: May 19, 2025 by: CNBC
Sentiment: Neutral
Regeneron Pharmaceuticals is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction. The drugmaker is buying 23andMe's Personal Genome Service, Total Health and Research Services business lines, but not its telehealth subsidiary Lemonaid Health.
Read More
Regeneron to buy 23andMe out of bankruptcy for $256m
Published: May 19, 2025 by: Proactive Investors
Sentiment: Neutral
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has agreed to buy genetic testing company 23andMe for $256 million, two months after the biotech firm filed for Chapter 11 bankruptcy. The deal includes 23andMe's consumer DNA testing and health research services, but excludes its telehealth arm, Lemonaid Health, which is being shut down.
Read More
23andMe sells its most valuable asset. Regeneron promises keep your DNA private.
Published: May 19, 2025 by: Market Watch
Sentiment: Negative
Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in the third quarter of this year.
Read More
Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
Published: May 19, 2025 by: WSJ
Sentiment: Positive
Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe's assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup.
Read More
Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million
Published: May 19, 2025 by: Reuters
Sentiment: Negative
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said on Monday.
Read More
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe's customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase to strengthen Regeneron's ongoing leadership in genetics-guided research and drug development to help people with serious diseases TARRYTOWN, N.Y., May 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced it has been named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co., a leading human genetics and biotechnology company.
Read More
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Adam Kovalčík , 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world's largest pre-college STEM competition in Columbus, Ohio
Read More
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market
Read More
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
Published: May 14, 2025 by: Barrons
Sentiment: Positive
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) BofA Securities 2025 Healthcare Conference (Transcript)
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc.
Read More
Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Regeneron Pharmaceuticals gets a buy rating today, agreeing with the Wall St consensus. Impressive are its drug discovery pipeline across several clinical segments, profit margins, and low Debt/Equity ratio. The firm just started paying dividends in February, so still lacks dividend growth data long-term.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies 18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies
Read More
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Negative
REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ryan Crowe - SVP, IR Leonard Schleifer - Board Co-Chair, Co-Founder, President and CEO George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - EVP, Commercial Chris Fenimore - EVP and CFO Conference Call Participants Tyler Van Buren - TD Cowen Alexandria Hammond - Wolfe Research Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Akash Tewari - Jefferies Carter Gould - Cantor William Pickering - Bernstein Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs …
Read More
Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More
Published: April 29, 2025 by: Investopedia
Sentiment: Positive
U.S. equities were higher at midday as markets waited for further clarification from the Trump administration about possible changes in tariff policy. The Dow Jones Industrial Average rose 0.6%, and the S&P 500 and Nasdaq were up by smaller percentages.
Read More
About Regeneron Pharmaceuticals, Inc. (REGN)
- IPO Date 1991-04-02
- Website https://www.regeneron.com
- Industry Biotechnology
- CEO Dr. Leonard S. Schleifer M.D., Ph.D.
- Employees 15158